Spero Therapeutics (SPRO) Change in Cash (2016 - 2026)
Spero Therapeutics posted quarterly Change in Cash of $15.9 million for Q1 2026, up 496.4% year-on-year from $2.7 million in Q1 2025, and up 289.97% on a QoQ basis from -$8.4 million in Q4 2025.
Spero Therapeutics (SPRO) has 11 years of Change in Cash data on file, last reported at $15.9 million in Q1 2026.
- For the quarter ending Q1 2026, Change in Cash rose 496.4% year-over-year to $15.9 million; the trailing twelve-month figure through Mar 2026 stood at $7.2 million (up 121.69% YoY), and the FY2025 full-year result was -$12.6 million, up 46.15% from the prior year.
- Change in Cash for Q1 2026 stood at $15.9 million, up from -$8.4 million in the prior quarter.
- Across five years, Change in Cash topped out at $58.7 million in Q4 2022 and bottomed at -$40.5 million in Q1 2022.
- The 5-year median for Change in Cash is -$8.4 million (2025), against an average of -$3.3 million.
- Peak annual rise in Change in Cash reached 21431.27% in 2022, while the deepest fall reached 395.57% in 2022.
- A 5-year view of Change in Cash shows it stood at $58.7 million in 2022, then plunged by 129.82% to -$17.5 million in 2023, then plunged by 33.78% to -$23.4 million in 2024, then soared by 64.31% to -$8.4 million in 2025, then jumped by 289.97% to $15.9 million in 2026.
- The last three Change in Cash figures came in at $15.9 million (Q1 2026), -$8.4 million (Q4 2025), and $17.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 2.44 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 623.00 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -2.44 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 417.10 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | -153.10 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 53.61 Mn |
| 10 | Spero Therapeutics | 162.39 Mn | 106.26 Mn | - | 15.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.86 Mn |
| Dec 31, 2025 | -8.35 Mn |
| Sep 30, 2025 | 17.42 Mn |
| Jun 30, 2025 | -17.69 Mn |
| Mar 31, 2025 | -4.00 Mn |
| Dec 31, 2024 | -23.40 Mn |
| Sep 30, 2024 | 12.76 Mn |
| Jun 30, 2024 | -18.74 Mn |
| Mar 31, 2024 | 5.94 Mn |
| Dec 31, 2023 | -17.49 Mn |
| Sep 30, 2023 | 16.14 Mn |
| Jun 30, 2023 | -18.56 Mn |
| Mar 31, 2023 | -12.85 Mn |
| Dec 31, 2022 | 58.66 Mn |
| Sep 30, 2022 | 5.05 Mn |
| Jun 30, 2022 | -26.71 Mn |
| Mar 31, 2022 | -40.47 Mn |
| Dec 31, 2021 | -275,000.00 |
| Sep 30, 2021 | 41.30 Mn |
| Jun 30, 2021 | -5.48 Mn |
| Mar 31, 2021 | -8.17 Mn |
| Dec 31, 2020 | -40.03 Mn |
| Sep 30, 2020 | 59.90 Mn |
| Jun 30, 2020 | 979,000.00 |
| Mar 31, 2020 | 34.63 Mn |
| Dec 31, 2019 | -15.87 Mn |
| Sep 30, 2019 | -25.54 Mn |
| Jun 30, 2019 | 21.74 Mn |
| Mar 31, 2019 | 15.32 Mn |
| Dec 31, 2018 | -6.40 Mn |
| Sep 30, 2018 | -8.24 Mn |
| Jun 30, 2018 | -3.84 Mn |
| Mar 31, 2018 | -34.79 Mn |
| Dec 31, 2017 | 61.92 Mn |
| Sep 30, 2017 | -10.93 Mn |
| Jun 30, 2017 | -10.04 Mn |
| Mar 31, 2017 | 36.02 Mn |
| Dec 31, 2016 | -965,000.00 |